Abstract
Pancreatic cancer is one of the most lethal cancers and leading cause of cancer related death worldwide. Due to its nonspecific early symptoms, pancreatic cancer is difficult to diagnose before extensive local invasion and distant metastasis. The 5-year survival rate of patients diagnosed with pancreatic cancer is less than 5%. Their median survival time is less than 12 months. The molecular mechanisms of pancreatic tumor genesis are poorly understood. Mesothelin is a glycosylphosphatidylinositol (GPI) anchored cell surface protein, which has been found overexpressed in human pancreatic cancer. The function of mesothelin in tumor progression remains unclear. This review aims to outline the roles of mesothelin in pancreatic cancer cell proliferation, apoptosis and invasion, as well as its potential role in mesothelintargeted cancer therapy. Therefore, mesothelin is malignant factor for pancreatic cancer and could be exploited as an antigenic target of therapeutic cancer vaccine.
Keywords: Function, mesothelin, pancreatic cancer.
Current Signal Transduction Therapy
Title:Clinical Significance of Mesothelin in Pancreatic Cancer
Volume: 11 Issue: 1
Author(s): Lei Zhang, Xiaoling Ni and Dayong Jin
Affiliation:
Keywords: Function, mesothelin, pancreatic cancer.
Abstract: Pancreatic cancer is one of the most lethal cancers and leading cause of cancer related death worldwide. Due to its nonspecific early symptoms, pancreatic cancer is difficult to diagnose before extensive local invasion and distant metastasis. The 5-year survival rate of patients diagnosed with pancreatic cancer is less than 5%. Their median survival time is less than 12 months. The molecular mechanisms of pancreatic tumor genesis are poorly understood. Mesothelin is a glycosylphosphatidylinositol (GPI) anchored cell surface protein, which has been found overexpressed in human pancreatic cancer. The function of mesothelin in tumor progression remains unclear. This review aims to outline the roles of mesothelin in pancreatic cancer cell proliferation, apoptosis and invasion, as well as its potential role in mesothelintargeted cancer therapy. Therefore, mesothelin is malignant factor for pancreatic cancer and could be exploited as an antigenic target of therapeutic cancer vaccine.
Export Options
About this article
Cite this article as:
Zhang Lei, Ni Xiaoling and Jin Dayong, Clinical Significance of Mesothelin in Pancreatic Cancer, Current Signal Transduction Therapy 2016; 11(1) . https://dx.doi.org/10.2174/1574362411666160210232918
DOI https://dx.doi.org/10.2174/1574362411666160210232918 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Folate Receptor Targeted Liposomes
Drug Design Reviews - Online (Discontinued) Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Surgical Options for Management of Malignant Pleural Mesothelioma in the Current Era
Current Respiratory Medicine Reviews An <i>In vivo</i> Immunohistochemical Study on MacroH2A.1 in Lung and Lymph-Node Tissues Exposed to an Asbestiform Fiber
Current Molecular Medicine The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design Editorial: New Strategies and Applications for Drugs Targeting EGFR and c-Met
Current Drug Targets Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Preface: MicroRNA as Disease Biomarkers
MicroRNA Sequential Bilateral Internal Jugular Vein Thrombosis: A Case Report and Review of this Rare Medical Entity
Vascular Disease Prevention (Discontinued) Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective
Current Topics in Medicinal Chemistry Synthesis and Antiproliferative Activity of Substituted 3[2-(1H-indol-3-yl)- 1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]pyridines, Marine Alkaloid Nortopsentin Analogues
Current Medicinal Chemistry Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology